pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
Sep 21, 26
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
Sep 21, 26
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
Sep 20, 26
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
Sep 20, 26
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
fiercebiotech
Sep 18, 26
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
Sep 18, 26
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
biospace
Sep 18, 26
STAT+: Roche expands its Boston footprint with new research center
stat
Sep 18, 26
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
biospace
Sep 17, 26
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
Sep 17, 26
FDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type A
endpoints
Sep 17, 26
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
fda press
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
The Endpoints 11: How we picked 2026's most exciting biotech startups
endpoints
Sep 17, 26
Webinar: Manufacturing in Turbulent Times
biospace
Sep 17, 26
STAT+: A Sellas immunotherapy study, long delayed, will end in failure
stat
Sep 17, 26
STAT+: A biotech hedge fund births a new immunology company
stat
Sep 16, 26
Skyhawk racks up more support for Huntington’s drug
biopharma dive
Sep 16, 26
AI is changing the talent biotech companies compete to hire
biospace
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Sep 15, 26
Newly formed Jaguar acquires Afib device assets from J&J
fiercebiotech
Sep 15, 26
Blood centers can help biopharma scale cell and gene therapies
biospace
Sep 14, 26
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
Sep 14, 26
Scholar Rock SMA drug approved by FDA
biopharma dive
Sep 14, 26
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
Sep 14, 26
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
Sep 11, 26
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
stat
Sep 11, 26
STAT+: Cancer drug shortages keep disrupting patient care
stat
Sep 11, 26
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
Sep 11, 26
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
Sep 11, 26
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
stat
← prev
page 8 of 18
next →